top of page

Verastem's CEO Dan Paterson discusses the launch of the Avmapki Fakzynja Co-Pack for KRAS-mutated recurrent low-grade serous ovarian cancer, and other pipeline projects

  • Sep 8, 2025
  • 1 min read

He discusses the launch of this combination, which was an accelerated approval, and arrived a couple of months sooner than the scheduled FDA decision date. Plus, why the confirmatory study is important, and pipeline progress on the G12D space.




Coverage brought to you by:


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page